Disclosure: Dr. Banaschewski has served as a consultant for Desitin, Eli Lilly, Medice, Novartis, Pfizer, Shire, and UCB. He received conference attendance support and conference support or served on the speaker’s bureau of Eli Lilly, Janssen McNeil, Medice, Novartis, Shire, and UCB. He has served on the advisory board for Eli Lilly, Medice, Novartis, Pfizer, Shire, and UCB. He is involved in clinical trials conducted by Eli Lilly and Novartis. Dr. Sonuga-Barke has served on the speaker’s bureau of and as a consultant for Shire and UCB. He has received research support from Janssen Cilag, Shire, and Qbtech. He has served on the advisory board for Shire, Flynn, UCB, and AstraZeneca. He has received conference support from Shire. Dr. Coghill has been on the advisory board for Cephalon, Eli Lilly, Janssen Cilag, Pfizer, Shire, and UCB. He has served as a consultant for Shire and Flynn. He has served on the speaker’s bureau of Janssen Cilag, Shire, UCB, Flynn, and Medice. He has received research funding from Eli Lilly, Janssen Cilag, and Shire. Dr. Buitelaar has served as a consultant and on the advisory board for Shire, Janssen Cilag, Eli Lilly, Pfizer, Organon, UCB, Servier, and Otsuka. He has served on the speaker’s bureau of Janssen Cilag and Eli Lilly. He has received research funding from Shire. Dr. Zuddas has served on the advisory boards for Eli Lilly, Shire, UCB, Astra Zeneca, and Otsuka. He has served on the speaker’s bureau of Eli Lilly and Sanofi-Aventis. He has received research funding from Eli Lilly and Shire. Dr. Sergeant has served on the speaker’s bureau of Eli Lilly, Janssen Cilag, and Shire. He has served on the advisory board for Eli Lilly and Shire. He has received research funding from Eli Lilly. He has received educational grants from Eli Lilly, Janssen Cilag, and Shire. Dr. Taylor reports no conflicts of interest.

Vol 48 - N° 11

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.